• Home
  • About
  • Repositories
  • Search
  • Web API
  • Feedback
<< Go Back

Metadata

Name
A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)
Repository
ClinicalTrials.gov
Identifier
clinicaltrials:NCT02955550
Description
This study will find the highest acceptable treatment dose and timing of infusion of cord
blood, culture expanded natural killer (NK) cells, a kind of immune cell, in patients with
multiple myeloma.

The NK cells will be given at varying days post autologous stem cell transplant. rhIL-2 is
administered after treatment to help the NK cells expand in the body. The safety of this
treatment will be studied and researchers want to learn if NK cells will help in treating
multiple myeloma.
Data or Study Types
clinical trial
Keywords
Multiple Myeloma, Plasma Cell Myeloma, Human IL-2, Bone Marrow Transplant, Relapsed/refractory Myeloma, PNK-007, Recombinant Human IL-2 (RHIL-2), Plasma Cell Neoplasm
Source Organization
Unknown
Access Conditions
available
Year
2016
Access Hyperlink
https://clinicaltrials.gov/ct2/show/NCT02955550

Distributions

  • Encoding Format: HTML ; URL: https://clinicaltrials.gov/ct2/show/results/NCT02955550
cellscelltreatmentstudycordbloodkillerstempostbody
This project was funded in part by grant U24AI117966 from the NIH National Institute of Allergy and Infectious Diseases as part of the Big Data to Knowledge program. We thank all members of the bioCADDIE community for their valuable input on the overall project.